The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Risk-adjusted safety analysis of pacritinib for patients with MF
In this video, Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the risk-adjusted safety analysis of pacritinib, a novel JAK inhibitor, for the treatment of patients with myelofibrosis (MF). Dr Pemmaraju first provides some background information on the approval of pacritinib and then discusses the safety and efficacy of pacritinib versus best available therapy in patients with MF. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
